Improved renal allograft survival following donor-specific transfusions. III: Kinetics of mixed lymphocyte culture responses before and after transplantation

The essence of the clonal deletion model of the donor-specific transfusion (DST) effect is synergy between DST-priming and post-transplant immunosuppression. Using a sensitive kinetics assay of the mixed lymphocyte culture (MLC) response to donor and third-party stimulators, we compared the response...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transplantation 1988, Vol.45 (1), p.127-132
Hauptverfasser: BURLINGHAM, W. J, GRAILER, A, SONDEL, P. M, SOLLINGER, H. W
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 132
container_issue 1
container_start_page 127
container_title Transplantation
container_volume 45
creator BURLINGHAM, W. J
GRAILER, A
SONDEL, P. M
SOLLINGER, H. W
description The essence of the clonal deletion model of the donor-specific transfusion (DST) effect is synergy between DST-priming and post-transplant immunosuppression. Using a sensitive kinetics assay of the mixed lymphocyte culture (MLC) response to donor and third-party stimulators, we compared the responses of controls (non-transfused healthy individuals) with those of patients who either had no rejection episodes in the first week posttransplant (group 1) or who had DST-type (greater than 3d onset) rejection episodes (group 2). We found that group 2 patients had normal or above-normal MLC responses after DST plus azathioprine (AZA) pretransplant treatment, but had a reduced/delayed posttransplant anti-donor MLC following reversal of early rejections (P = .05 compared with controls). Group 1 patients had a nonspecifically reduced MLC after DST + AZA treatment (P less than .02 compared with controls), while posttransplant MLC responses showed a return to normal (pretransfusion) levels. These data suggest a synergy of DST with immunosuppressive drug that induced MLC hyporesponsiveness, but only in patients who received anti-lymphoblast globulin or a sustained high dose immunosuppression in the early posttransplant period.
doi_str_mv 10.1097/00007890-198801000-00028
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_78098163</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>14856739</sourcerecordid><originalsourceid>FETCH-LOGICAL-p181t-6645bf1a1da9f472196af54991a875b6c448aa5b4c77b4fffd45c1f304e6387b3</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi1EVZaWn4DkA-KWYq8df3BDFR8RlbjQ82ri2MXIiYPtbNkfw39lpK64Ymlk-Z1n3vEMIZSzG86sfsfwaGNZx60xjOOrw9ibZ2THeyE7xQx7TnaMSd5xIfQL8rLWn4j0QutLcrm3ai-k3pE_w7yWfPQTLX6BRCGl_FAgNFq3coxHlEJG7TEuD3TKSy5dXb2LITraCiw1bDXmpd7QYRje069x8S26SnOgc_yNtuk0rz-yOzVP3ZbaVjx2qiuW-EpHHzIKsEwUW_ryZLkmWBo0tL0mFwFS9a_O9xW5__Tx--2X7u7b5-H2w123csNbp5Tsx8CBT2CD1HtuFYReWsvB6H5UTkoD0I_SaT3KEMIke8eDYNIrYfQorsjbJ1_cxa_N13aYY3U-4Ud83upBG2YNV-K_IJemV1pYBF-fwW2c_XRYS5yhnA7nxWP-zTkP1UEKOLeL9R-m0UQqLv4CScyXmw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>14856739</pqid></control><display><type>article</type><title>Improved renal allograft survival following donor-specific transfusions. III: Kinetics of mixed lymphocyte culture responses before and after transplantation</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>BURLINGHAM, W. J ; GRAILER, A ; SONDEL, P. M ; SOLLINGER, H. W</creator><creatorcontrib>BURLINGHAM, W. J ; GRAILER, A ; SONDEL, P. M ; SOLLINGER, H. W</creatorcontrib><description>The essence of the clonal deletion model of the donor-specific transfusion (DST) effect is synergy between DST-priming and post-transplant immunosuppression. Using a sensitive kinetics assay of the mixed lymphocyte culture (MLC) response to donor and third-party stimulators, we compared the responses of controls (non-transfused healthy individuals) with those of patients who either had no rejection episodes in the first week posttransplant (group 1) or who had DST-type (greater than 3d onset) rejection episodes (group 2). We found that group 2 patients had normal or above-normal MLC responses after DST plus azathioprine (AZA) pretransplant treatment, but had a reduced/delayed posttransplant anti-donor MLC following reversal of early rejections (P = .05 compared with controls). Group 1 patients had a nonspecifically reduced MLC after DST + AZA treatment (P less than .02 compared with controls), while posttransplant MLC responses showed a return to normal (pretransfusion) levels. These data suggest a synergy of DST with immunosuppressive drug that induced MLC hyporesponsiveness, but only in patients who received anti-lymphoblast globulin or a sustained high dose immunosuppression in the early posttransplant period.</description><identifier>ISSN: 0041-1337</identifier><identifier>EISSN: 1534-6080</identifier><identifier>DOI: 10.1097/00007890-198801000-00028</identifier><identifier>PMID: 2962347</identifier><identifier>CODEN: TRPLAU</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Azathioprine - administration &amp; dosage ; Biological and medical sciences ; Blood Transfusion ; Clone Cells - immunology ; Graft Enhancement, Immunologic ; Graft Rejection ; Humans ; Immunosuppression ; Kidney Transplantation ; Lymphocyte Activation ; Lymphocyte Culture Test, Mixed ; Lymphocyte Depletion ; Medical sciences ; Models, Biological ; Premedication ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the urinary system ; Tissue Donors</subject><ispartof>Transplantation, 1988, Vol.45 (1), p.127-132</ispartof><rights>1988 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=7673461$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2962347$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BURLINGHAM, W. J</creatorcontrib><creatorcontrib>GRAILER, A</creatorcontrib><creatorcontrib>SONDEL, P. M</creatorcontrib><creatorcontrib>SOLLINGER, H. W</creatorcontrib><title>Improved renal allograft survival following donor-specific transfusions. III: Kinetics of mixed lymphocyte culture responses before and after transplantation</title><title>Transplantation</title><addtitle>Transplantation</addtitle><description>The essence of the clonal deletion model of the donor-specific transfusion (DST) effect is synergy between DST-priming and post-transplant immunosuppression. Using a sensitive kinetics assay of the mixed lymphocyte culture (MLC) response to donor and third-party stimulators, we compared the responses of controls (non-transfused healthy individuals) with those of patients who either had no rejection episodes in the first week posttransplant (group 1) or who had DST-type (greater than 3d onset) rejection episodes (group 2). We found that group 2 patients had normal or above-normal MLC responses after DST plus azathioprine (AZA) pretransplant treatment, but had a reduced/delayed posttransplant anti-donor MLC following reversal of early rejections (P = .05 compared with controls). Group 1 patients had a nonspecifically reduced MLC after DST + AZA treatment (P less than .02 compared with controls), while posttransplant MLC responses showed a return to normal (pretransfusion) levels. These data suggest a synergy of DST with immunosuppressive drug that induced MLC hyporesponsiveness, but only in patients who received anti-lymphoblast globulin or a sustained high dose immunosuppression in the early posttransplant period.</description><subject>Azathioprine - administration &amp; dosage</subject><subject>Biological and medical sciences</subject><subject>Blood Transfusion</subject><subject>Clone Cells - immunology</subject><subject>Graft Enhancement, Immunologic</subject><subject>Graft Rejection</subject><subject>Humans</subject><subject>Immunosuppression</subject><subject>Kidney Transplantation</subject><subject>Lymphocyte Activation</subject><subject>Lymphocyte Culture Test, Mixed</subject><subject>Lymphocyte Depletion</subject><subject>Medical sciences</subject><subject>Models, Biological</subject><subject>Premedication</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the urinary system</subject><subject>Tissue Donors</subject><issn>0041-1337</issn><issn>1534-6080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhi1EVZaWn4DkA-KWYq8df3BDFR8RlbjQ82ri2MXIiYPtbNkfw39lpK64Ymlk-Z1n3vEMIZSzG86sfsfwaGNZx60xjOOrw9ibZ2THeyE7xQx7TnaMSd5xIfQL8rLWn4j0QutLcrm3ai-k3pE_w7yWfPQTLX6BRCGl_FAgNFq3coxHlEJG7TEuD3TKSy5dXb2LITraCiw1bDXmpd7QYRje069x8S26SnOgc_yNtuk0rz-yOzVP3ZbaVjx2qiuW-EpHHzIKsEwUW_ryZLkmWBo0tL0mFwFS9a_O9xW5__Tx--2X7u7b5-H2w123csNbp5Tsx8CBT2CD1HtuFYReWsvB6H5UTkoD0I_SaT3KEMIke8eDYNIrYfQorsjbJ1_cxa_N13aYY3U-4Ud83upBG2YNV-K_IJemV1pYBF-fwW2c_XRYS5yhnA7nxWP-zTkP1UEKOLeL9R-m0UQqLv4CScyXmw</recordid><startdate>1988</startdate><enddate>1988</enddate><creator>BURLINGHAM, W. J</creator><creator>GRAILER, A</creator><creator>SONDEL, P. M</creator><creator>SOLLINGER, H. W</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>1988</creationdate><title>Improved renal allograft survival following donor-specific transfusions. III: Kinetics of mixed lymphocyte culture responses before and after transplantation</title><author>BURLINGHAM, W. J ; GRAILER, A ; SONDEL, P. M ; SOLLINGER, H. W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p181t-6645bf1a1da9f472196af54991a875b6c448aa5b4c77b4fffd45c1f304e6387b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Azathioprine - administration &amp; dosage</topic><topic>Biological and medical sciences</topic><topic>Blood Transfusion</topic><topic>Clone Cells - immunology</topic><topic>Graft Enhancement, Immunologic</topic><topic>Graft Rejection</topic><topic>Humans</topic><topic>Immunosuppression</topic><topic>Kidney Transplantation</topic><topic>Lymphocyte Activation</topic><topic>Lymphocyte Culture Test, Mixed</topic><topic>Lymphocyte Depletion</topic><topic>Medical sciences</topic><topic>Models, Biological</topic><topic>Premedication</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the urinary system</topic><topic>Tissue Donors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BURLINGHAM, W. J</creatorcontrib><creatorcontrib>GRAILER, A</creatorcontrib><creatorcontrib>SONDEL, P. M</creatorcontrib><creatorcontrib>SOLLINGER, H. W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BURLINGHAM, W. J</au><au>GRAILER, A</au><au>SONDEL, P. M</au><au>SOLLINGER, H. W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improved renal allograft survival following donor-specific transfusions. III: Kinetics of mixed lymphocyte culture responses before and after transplantation</atitle><jtitle>Transplantation</jtitle><addtitle>Transplantation</addtitle><date>1988</date><risdate>1988</risdate><volume>45</volume><issue>1</issue><spage>127</spage><epage>132</epage><pages>127-132</pages><issn>0041-1337</issn><eissn>1534-6080</eissn><coden>TRPLAU</coden><abstract>The essence of the clonal deletion model of the donor-specific transfusion (DST) effect is synergy between DST-priming and post-transplant immunosuppression. Using a sensitive kinetics assay of the mixed lymphocyte culture (MLC) response to donor and third-party stimulators, we compared the responses of controls (non-transfused healthy individuals) with those of patients who either had no rejection episodes in the first week posttransplant (group 1) or who had DST-type (greater than 3d onset) rejection episodes (group 2). We found that group 2 patients had normal or above-normal MLC responses after DST plus azathioprine (AZA) pretransplant treatment, but had a reduced/delayed posttransplant anti-donor MLC following reversal of early rejections (P = .05 compared with controls). Group 1 patients had a nonspecifically reduced MLC after DST + AZA treatment (P less than .02 compared with controls), while posttransplant MLC responses showed a return to normal (pretransfusion) levels. These data suggest a synergy of DST with immunosuppressive drug that induced MLC hyporesponsiveness, but only in patients who received anti-lymphoblast globulin or a sustained high dose immunosuppression in the early posttransplant period.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott</pub><pmid>2962347</pmid><doi>10.1097/00007890-198801000-00028</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0041-1337
ispartof Transplantation, 1988, Vol.45 (1), p.127-132
issn 0041-1337
1534-6080
language eng
recordid cdi_proquest_miscellaneous_78098163
source MEDLINE; Journals@Ovid Complete
subjects Azathioprine - administration & dosage
Biological and medical sciences
Blood Transfusion
Clone Cells - immunology
Graft Enhancement, Immunologic
Graft Rejection
Humans
Immunosuppression
Kidney Transplantation
Lymphocyte Activation
Lymphocyte Culture Test, Mixed
Lymphocyte Depletion
Medical sciences
Models, Biological
Premedication
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Surgery of the urinary system
Tissue Donors
title Improved renal allograft survival following donor-specific transfusions. III: Kinetics of mixed lymphocyte culture responses before and after transplantation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T14%3A19%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improved%20renal%20allograft%20survival%20following%20donor-specific%20transfusions.%20III:%20Kinetics%20of%20mixed%20lymphocyte%20culture%20responses%20before%20and%20after%20transplantation&rft.jtitle=Transplantation&rft.au=BURLINGHAM,%20W.%20J&rft.date=1988&rft.volume=45&rft.issue=1&rft.spage=127&rft.epage=132&rft.pages=127-132&rft.issn=0041-1337&rft.eissn=1534-6080&rft.coden=TRPLAU&rft_id=info:doi/10.1097/00007890-198801000-00028&rft_dat=%3Cproquest_pubme%3E14856739%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=14856739&rft_id=info:pmid/2962347&rfr_iscdi=true